A Stevenson1, K Wakeham2, J Pan3, K Kavanagh3, D Millan4, S Bell4, D McLellan4, S V Graham1, K Cuschieri5. 1. Centre for Virus Research, Institute of Infection Immunity and Inflammation, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. 2. Sussex Cancer Centre, Brighton, UK. 3. Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK. 4. Department of Pathology, The Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK. 5. Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh, UK. Electronic address: Kate.Cuschieri@nhslothian.scot.nhs.uk.
Abstract
BACKGROUND: Although HPV-positive oropharyngeal cancer (OPC) patients have improved prognosis compared to HPV negative patients; there remains an HPV-positive group who have poor outcomes. Biomarkers to stratify discrete patient outcomes are thus desirable. Our objective was to analyse viral load (VL) by droplet digital PCR (ddPCR), in HPV-positive patients with OPC on whom clinical outcome data were available. METHODS: In a cohort of patients that had previously tested HPV positive via conventional PCR, VL was determined using ddPCR assays for HPV16 L1 and E6 genes. VL was classed as "medium/high" if more than 5.57 copies or 8.68 copies of the HPV 16 L1 or E6 gene were detected respectively. Effect of VL on overall survival and hazard of death & disease progression was performed with adjustments made for sex, age, deprivation, smoking, alcohol consumption and stage. RESULTS: L1 VL ranged from 0.0014-304 gene copies per cell with a mean of 30.9; comparatively E6 VL ranged from 0.0012-356 copies per cell with a mean of 37.9. Univariate analysis showed those with a medium/high VL had a lower hazard of death; this was significant for L1 (p = 0.02) but not for E6 (p = 0.67). The ratio of E6 to L1 deviated from n = 1 in most samples but had no influence on clinical outcomes. CONCLUSIONS: HPV viral load may be informative for the further stratification of clinical outcomes in HPV positive OPC patients.
BACKGROUND: Although HPV-positive oropharyngeal cancer (OPC) patients have improved prognosis compared to HPV negative patients; there remains an HPV-positive group who have poor outcomes. Biomarkers to stratify discrete patient outcomes are thus desirable. Our objective was to analyse viral load (VL) by droplet digital PCR (ddPCR), in HPV-positive patients with OPC on whom clinical outcome data were available. METHODS: In a cohort of patients that had previously tested HPV positive via conventional PCR, VL was determined using ddPCR assays for HPV16 L1 and E6 genes. VL was classed as "medium/high" if more than 5.57 copies or 8.68 copies of the HPV 16 L1 or E6 gene were detected respectively. Effect of VL on overall survival and hazard of death & disease progression was performed with adjustments made for sex, age, deprivation, smoking, alcohol consumption and stage. RESULTS: L1 VL ranged from 0.0014-304 gene copies per cell with a mean of 30.9; comparatively E6 VL ranged from 0.0012-356 copies per cell with a mean of 37.9. Univariate analysis showed those with a medium/high VL had a lower hazard of death; this was significant for L1 (p = 0.02) but not for E6 (p = 0.67). The ratio of E6 to L1 deviated from n = 1 in most samples but had no influence on clinical outcomes. CONCLUSIONS: HPV viral load may be informative for the further stratification of clinical outcomes in HPV positive OPC patients.
Authors: John Charles Rotondo; Lucia Oton-Gonzalez; Chiara Mazziotta; Carmen Lanzillotti; Maria Rosa Iaquinta; Mauro Tognon; Fernanda Martini Journal: Front Microbiol Date: 2020-11-19 Impact factor: 5.640
Authors: Katarzyna D Kania; Daria Haręża; Jacek R Wilczyński; Miłosz Wilczyński; Dariusz Jarych; Andrzej Malinowski; Edyta Paradowska Journal: Cells Date: 2022-10-05 Impact factor: 7.666
Authors: Natalie N Kinloch; Gordon Ritchie; Winnie Dong; Kyle D Cobarrubias; Hanwei Sudderuddin; Tanya Lawson; Nancy Matic; Julio S G Montaner; Victor Leung; Marc G Romney; Christopher F Lowe; Chanson J Brumme; Zabrina L Brumme Journal: J Mol Diagn Date: 2021-05-29 Impact factor: 5.568